We are preparing the requested document. Please wait, this may take a while...!
|Application / Reactivity||Mouse (Murine)||Human|
|ELISA||19 Antibodies||27 Antibodies|
|Enzyme Immunoassay (EIA)||1 Antibodies||3 Antibodies|
|Flow Cytometry (FACS)||1 Antibodies||1 Antibodies|
|Immunocytochemistry (ICC)||1 Antibodies||5 Antibodies|
|Immunofluorescence (IF)||8 Antibodies||28 Antibodies|
|Immunofluorescence (Paraffin-embedded Sections) (IF (p))||22 Antibodies||22 Antibodies|
|Immunohistochemistry (IHC)||10 Antibodies||20 Antibodies|
|Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))||8 Antibodies|
|Immunoprecipitation (IP)||3 Antibodies|
|Western Blotting (WB)||35 Antibodies|
|Immunohistochemistry (Formalin-fixed Paraffin-embedded Sections) (IHC (fp))||1 Antibodies|
|Immunohistochemistry (Frozen Sections) (IHC (fro))||2 Antibodies|
|Antigen||V-Ha-Ras Harvey Rat Sarcoma Viral Oncogene Homolog (HRAS) Antibodies|
|Epitope||AA 146-176, C-Term Alternatives|
|Reactivity||Human, Mouse (Murine) Alternatives|
|Conjugate||This HRAS antibody is un-conjugated Alternatives|
Immunofluorescence (IF), Western Blotting (WB)
|4 references available|
|Supplier||Log in to see|
Product Details anti-HRAS AntibodyTarget Details HRAS Application Details Handling References for anti-HRAS Antibody (ABIN655622) Images
|Specificity||This HRAS antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 153-184 amino acids from the C-terminal region of human HRAS.|
|Predicted Reactivity||Chicken,Rat (Rattus)|
|Purification||This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.|
|Immunogen||This HRAS antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 146-176 AA from the C-terminal region of human HRAS.|
Target Details HRASProduct Details anti-HRAS Antibody Application Details Handling References for anti-HRAS Antibody (ABIN655622) Images back to top
|Alternative Name||HRAS (HRAS Antibody Abstract)|
This gene belongs to the Ras oncogene family, whose members are related to the transforming genes of mammalian sarcoma retroviruses. The products encoded by these genes function in signal transduction pathways. These proteins can bind GTP and GDP, and they have intrinsic GTPase activity. This protein undergoes a continuous cycle of de- and re-palmitoylation, which regulates its rapid exchange between the plasma membrane and the Golgi apparatus. Mutations in this gene cause Costello syndrome, a disease characterized by increased growth at the prenatal stage, growth deficiency at the postnatal stage, predisposition to tumor formation, mental retardation, skin and musculoskeletal abnormalities, distinctive facial appearance and cardiovascular abnormalities. Defects in this gene are implicated in a variety of cancers, including bladder cancer, follicular thyroid cancer, and oral squamous cell carcinoma. Multiple transcript variants, which encode different isoforms, have been identified for this gene.
Pathways: Neurotrophin signaling pathway, Hepatitis C, Insulin signaling pathway, Axon guidance, Regulation of actin cytoskeleton, MAPK signaling pathway, VEGF signaling pathway, Fc epsilon RI signaling pathway, Long-term depression, GnRH signaling pathway, Pathways in cancer, Non-small cell lung cancer, Chemokine signaling pathway, Natural killer cell mediated cytotoxicity, Focal adhesion, Endocytosis, T cell receptor signaling pathway, B cell receptor signaling pathway, Prostate cancer, Melanoma, Gap junction, Melanogenesis, Tight junction, Bladder cancer, Renal cell carcinoma, ErbB signaling pathway, Chronic myeloid leukemia, Endometrial cancer, Acute myeloid leukemia, Glioma, Thyroid cancer
|Molecular Weight||21298 Da|
|Research Area||Signaling, Cell Structure, Protein Modifications, Cancer, Chromatin|
|Pathways||p53 Signaling, MAPK Signaling, RTK Signaling, TCR Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway|
Application DetailsProduct Details anti-HRAS Antibody Target Details HRAS Handling References for anti-HRAS Antibody (ABIN655622) Images back to top
|Application Notes||WB = 1:1000, IF = 1:10-50|
|Restrictions||For Research Use only|
HandlingProduct Details anti-HRAS Antibody Target Details HRAS Application Details References for anti-HRAS Antibody (ABIN655622) Images back to top
|Buffer||PBS with 0.09 % (W/V) sodium azide|
|Precaution of Use||This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.|
|Storage||4 °C/-20 °C|
|Storage Comment||Maintain refrigerated at 2-8 °C for up to 6 months. For long term storage store at -20 °C in small aliquots to prevent freeze-thaw cycles.|
|Expiry Date||6 months|
References for anti-HRAS Antibody (ABIN655622)Product Details anti-HRAS Antibody Target Details HRAS Application Details Handling Images back to top
van Engen-van Grunsven, van Dijk, Ruiter et al.: "HRAS-mutated Spitz tumors: A subtype of Spitz tumors with distinct features." in: The American journal of surgical pathology, Vol. 34, Issue 10, pp. 1436-41, 2010 (PubMed).
Kwack, Song, Pyun et al.: "[Study on association between an H-RAS gene polymorphism and gastric cancer development]." in: The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, Vol. 56, Issue 2, pp. 78-82, 2010 (PubMed).
Ma, Liu, Wu et al.: "p66(Shc) restrains Ras hyperactivation and suppresses metastatic behavior." in: Oncogene, Vol. 29, Issue 41, pp. 5559-67, 2010 (PubMed).
Li, Wang, Liu et al.: "Transcriptional factor HBP1 targets P16(INK4A), upregulating its expression and consequently is involved in Ras-induced premature senescence." in: Oncogene, Vol. 29, Issue 36, pp. 5083-94, 2010 (PubMed).
ImagesProduct Details anti-HRAS Antibody Target Details HRAS Application Details Handling References for anti-HRAS Antibody (ABIN655622) back to top